J. Goldman & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

J. Goldman & Co’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-150,611	Closed	-$562K	–	669
2024 Q3	$562K	Sell	150,611 -40,500	-21%	-$193K	0.02%	340
2024 Q2	$1.07M	Sell	191,111 -67,585	-26%	-$294K	0.03%	295
2024 Q1	$1.36M	Buy	258,696 +12,271	+5%	+$67.3K	0.04%	246
2023 Q4	$1.29M	Buy	+246,425	New	+$2.43M	0.05%	220
2022 Q1	–	Sell	-75,646	Closed	-$3.85M	–	474
2021 Q4	$3.85M	Buy	75,646 +47,118	+165%	+$2.44M	0.21%	131
2021 Q3	$1.59M	Buy	+28,528	New	+$1.4M	0.08%	209
2016 Q2	–	Sell	-1,700	Closed	-$69K	–	423
2016 Q1	$69K	Buy	+1,700	New	+$108K	﹤0.01%	279

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

J. Goldman & Co's EGRX Position: Q4 2024 in Review

J. Goldman & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 150,611 shares — an estimated $562K sold.

J. Goldman & Co first reported a position in EGRX in Q1 2016 and held it in 7 quarters. The position peaked at $3.85M in Q4 2021. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

J. Goldman & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
J. Goldman & Co sold 150,611 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $562K.
J. Goldman & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 7 quarters.
J. Goldman & Co's Eagle Pharmaceuticals, Inc. position peaked at $3.85M in Q4 2021.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.